Literature DB >> 26975710

Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Allison L Kuipers1, Candace M Kammerer2, J Howard Pratt2, Clareann H Bunker2, Victor W Wheeler2, Alan L Patrick2, Joseph M Zmuda2.   

Abstract

Hypertension is associated with accelerated bone loss, and the renin-angiotensin-aldosterone system is a key regulator of blood pressure. Although components of this system are expressed in human bone cells, studies in humans are sparse. Thus, we studied the association of circulating renin and aldosterone with osteocalcin and bone mineral density. We recruited 373 African ancestry family members without regard to health status from 6 probands (mean family size: 62 and relative pairs: 1687). Participants underwent a clinical examination, dual-energy x-ray absorptiometry, and quantitative computed tomographic scans. Renin activity, aldosterone concentration, and osteocalcin were measured in fasting blood samples. Aldosterone/renin ratio was calculated as aldosterone concentration/renin activity. All models were analyzed using pedigree-based variance components methods. Full models included adjustment for age, sex, body composition, comorbidities, lifestyle factors, blood pressure, and antihypertensive medication. Higher renin activity was significantly associated with lower total osteocalcin and with higher trabecular bone mineral density (both P<0.01). There were also significant genetic correlations between renin activity and whole-body bone mineral density. There were no associations with aldosterone concentration in any model and results for aldosterone/renin ratio were similar to those for renin activity. This is the first study to report a significant association between renin activity and a marker of bone turnover and bone mineral density in generally healthy individuals. Also, there is evidence for significant genetic pleiotropy and, thus, there may be a shared biological mechanism underlying both the renin-angiotensin-aldosterone system and bone metabolism that is independent of hypertension.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  aldosterone; bone density; hypertension; osteocalcin; renin

Mesh:

Substances:

Year:  2016        PMID: 26975710      PMCID: PMC4833607          DOI: 10.1161/HYPERTENSIONAHA.115.06837

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

1.  Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome.

Authors:  Motokuni Aoki; Hirohisa Kawahata; Daisuke Sotobayashi; Hisahiro Yu; Atsushi Moriguchi; Hironori Nakagami; Toshio Ogihara; Ryuichi Morishita
Journal:  Geriatr Gerontol Int       Date:  2014-11-03       Impact factor: 2.730

Review 2.  The vitamin K-dependent proteins: an update.

Authors:  G Ferland
Journal:  Nutr Rev       Date:  1998-08       Impact factor: 7.110

3.  Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

Authors:  R Hatton; M Stimpel; T J Chambers
Journal:  J Endocrinol       Date:  1997-01       Impact factor: 4.286

4.  Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis.

Authors:  Zhang Yongtao; Wang Kunzheng; Zheng Jingjing; Shan Hu; Kou Jianqiang; Liu Ruiyu; Wang Chunsheng
Journal:  Endocrine       Date:  2014-02-12       Impact factor: 3.633

5.  Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin.

Authors:  C M Gundberg; S D Nieman; S Abrams; H Rosen
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

6.  Bone health and aldosterone excess.

Authors:  L Ceccoli; V Ronconi; L Giovannini; M Marcheggiani; F Turchi; M Boscaro; G Giacchetti
Journal:  Osteoporos Int       Date:  2013-05-22       Impact factor: 4.507

Review 7.  Potential effect of angiotensin II receptor blockade in adipose tissue and bone.

Authors:  Hironori Nakagami; Mariana Kiomy Osako; Ryuichi Morishita
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Bone involvement in aldosteronism.

Authors:  Antonio Stefano Salcuni; Serena Palmieri; Vincenzo Carnevale; Valentina Morelli; Claudia Battista; Vito Guarnieri; Giuseppe Guglielmi; Gaetano Desina; Cristina Eller-Vainicher; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

9.  Bone and mineral metabolism in patients with primary aldosteronism.

Authors:  Luigi Petramala; Laura Zinnamosca; Amina Settevendemmie; Cristiano Marinelli; Matteo Nardi; Antonio Concistrè; Francesco Corpaci; Gianfranco Tonnarini; Giorgio De Toma; Claudio Letizia
Journal:  Int J Endocrinol       Date:  2014-04-03       Impact factor: 3.257

10.  Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.

Authors:  Suguru Yamamoto; Ryo Kido; Yoshihiro Onishi; Shingo Fukuma; Tadao Akizawa; Masafumi Fukagawa; Junichiro J Kazama; Ichiei Narita; Shunichi Fukuhara
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

View more
  3 in total

1.  Risk Factors Associated With Lower Bone Mineral Density in Primary Aldosteronism Patients.

Authors:  Xiaomei Lv; Huijun Hu; Chuyu Shen; Xiaoyun Zhang; Li Yan; Shaoling Zhang; Ying Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

2.  Mineralocorticoid Receptor Activation and Atrial Fibrosis.

Authors:  Nancy J Brown
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

3.  Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome.

Authors:  Wangna Tang; Yun Chai; Hongwei Jia; Baoping Wang; Tong Liu; Hao Wang; Chenlin Dai
Journal:  BMC Endocr Disord       Date:  2022-02-11       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.